title: Anticancer effects of the organosilicon multidrug resistance modulator SILA 421.
abstract: 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis{3-[1(4-butylpiperazinyl)]-propyl}-disiloxan-tetrahydrochlorid (SILA 421) is a compound that was developed as modulator of the ABC cassette transporter P-glycoprotein. Furthermore, it exerted antimicrobial toxicity, vascular effects, downregulation of chaperone induction and plasmid curing in bacterial cells. Here, this drug was found to possess cytotoxic activity against a panel of human cancer cell lines that do not overexpress P-gp, with 50% inhibitory concentrations ranging between 1.75±0.38 μM for GLC14 small cell lung cancer and 34.00±4.75 μM for PC-3 prostate cancer cells. HL-60 leukemia and MDA-MB-435 breast cancer cells exhibited cell cycle arrest and apoptotic cell death in response to SILA 421. Assessment of global gene expression of SILA 421-treated HL-60 cells was employed to identify cellular pathways affected by the compound and revealed disturbance of DNA replication, transcription and production of apparently misfolded proteins. Endoplasmatic reticulum stress and downregulation of cell cycle, cellular repair mechanisms and growth factor-related signaling cascades eventually resulted in induction of apoptosis in this cell line. In addition to the well established P-gp inhibitory effect of SILA compounds, reversal of resistance to taxanes, which had been reported for SILA 421 and the related molecule SILA 409, may be linked to downregulation of gene expression of kinesins. Interference with DNA replication and transcription seems to be the common denominator of antimicrobial activity and plasmid curing, as well as anticancer toxicity in human cell lines. Thus, in consideration of the full range of putative cellular targets found in the present work, the application of these SILA compounds for treatment of tumors should be further evaluated.
authors.affiliation: Ludwig Boltzmann Society, Cluster of Translational Oncology, Vienna, Austria.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Olszewski
authors.forename: Robert
authors.initials: R
authors.lastname: Zeillinger
authors.forename: Meltem Demirel
authors.initials: MD
authors.lastname: Kars
authors.forename: Attila
authors.initials: A
authors.lastname: Zalatnai
authors.forename: Jozsef
authors.initials: J
authors.lastname: Molnar
authors.forename: Gerhard
authors.initials: G
authors.lastname: Hamilton
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects; D018432:Drug Resistance, Multiple / Q000187:drug effects / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D018922:HL-60 Cells; D006801:Humans; D016547:Kinesins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D009928:Organ Specificity; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology*; D017510:Protein Folding; D015398:Signal Transduction / Q000187:drug effects; D012833:Siloxanes / Q000737:chemistry / Q000494:pharmacology*
chemical_list: C523096:1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-(1-(4-butypiperazinyl))propyl)disiloxane; D018435:ATP Binding Cassette Transporter, Subfamily B; D000970:Antineoplastic Agents; D010879:Piperazines; C509655:SILA-409; D012833:Siloxanes; D016547:Kinesins